Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cross Sectional Study
87%
Parkinson's Disease
87%
Systematic Review
46%
Randomized Controlled Trial
43%
Geriatrics
43%
Artificial Intelligence
43%
Medical Student
43%
Health Service
43%
Quality Improvement
43%
Uptake Rates
26%
Pathologist
21%
Nephropathy
21%
Clinician
21%
Health Care Cost
21%
Urine Sampling
21%
Water-Electrolyte Imbalance
21%
Urinary Tract Infection
21%
Parkinson's Disease Clinical Trial
17%
Clinical Trial
15%
Gerontology
11%
Post and Core
8%
Outcome Assessment
8%
Inferential Statistics
7%
Keyphrases
Clinical Trials
43%
Sorafenib
43%
Risk Outcomes
43%
Patient Outcomes
43%
Risk-benefit
43%
Patient Benefit
43%
Drug Development
43%
Patient Risk
43%
Gerontology
21%
Off-label Indications
18%
Lab Technicians
15%
FDA-approved Drugs
12%
Adverse Events
12%
Monotherapy
12%
Objective Response Rate
12%
Approved Indications
12%
Trialists
6%
Data Extraction
6%
Overall Response Rate
6%
Differentiated Thyroid Carcinoma
6%
Excessive Risk
6%
New Indication
6%
Response Criteria
6%
Adverse Event Rates
6%
Bibliographic Databases
6%
Cancer Treatment
6%
Trends over Time
6%
Drug Trials
6%
Trial Participants
6%
Cancer Drugs
6%
Median Overall Survival
6%
Literature Search
6%
Clinical Endpoints
6%
Pharmaceutical Companies
6%
Median Progression-free Survival
6%
Oncology Drugs
6%
FDA Approval
6%
Trial Characteristics
6%
Transformative Role
5%
Artificial Intelligence Era
5%
Label Setting
5%
Cumulative Rate
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
87%
Sorafenib
87%
Randomized Controlled Trial
43%
Parkinson's Disease
43%
Adverse Event
29%
Malignant Neoplasm
29%
Monotherapy
17%
Overall Survival
11%
Progression Free Survival
11%
Drug Screening
6%
Differentiated Thyroid Cancer
6%
Base
5%
Antitumor Activity
5%
Off-Label Use
5%
